The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
NMTC | -16.27% | -76.87% | -25.38% | -94% |
S&P | +15.06% | +95.03% | +14.29% | +172% |
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $1.70M | 105.4% |
Gross Profit | $0.91M | 224.6% |
Gross Margin | 53.94% | 19.8% |
Market Cap | $33.79M | 51.7% |
Market Cap / Employee | $1.99M | 0.0% |
Employees | 17 | 0.0% |
Net Income | -$1.50M | 45.8% |
EBITDA | -$1.82M | 33.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $8.04M | 396.3% |
Accounts Receivable | $0.00M | -100.0% |
Inventory | 1.9 | 5.8% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $0.18M | -16.5% |
Short Term Debt | $0.12M | 50.1% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | -67.85% | 159.0% |
Return On Invested Capital | -443.51% | -352.0% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | -$1.51M | 36.6% |
Operating Free Cash Flow | -$1.46M | 38.0% |
Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
---|---|---|---|---|---|
Price to Book | 9.15 | 30.97 | 8.93 | 18.91 | 246.15% |
Price to Sales | 8.58 | 2.91 | 3.02 | 3.42 | -38.62% |
Price to Tangible Book Value | 9.38 | 33.72 | 9.13 | 19.90 | 256.86% |
Enterprise Value to EBITDA | -10.33 | 13.91 | -9.73 | -13.86 | 84.15% |
Return on Equity | -348.4% | -195.5% | -265.2% | -95.4% | -72.68% |
Total Debt | $0.26M | $0.34M | $0.31M | $0.30M | 1.94% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.